220 related articles for article (PubMed ID: 33360170)
21. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for conversion to generalization in ocular myasthenia gravis.
Witthayaweerasak J; Rattanalert N; Aui-Aree N
Medicine (Baltimore); 2021 May; 100(19):e25899. PubMed ID: 34106649
[TBL] [Abstract][Full Text] [Related]
23. Pediatric Ocular Myasthenia Gravis: Single-Center Experience.
Kessi M; Tang Y; Chen B; Wang G; Zhang C; He F; Peng J; Yin F; Yang L
Pediatr Neurol; 2024 Apr; 153():137-143. PubMed ID: 38382246
[TBL] [Abstract][Full Text] [Related]
24. Safety of prednisone for ocular myasthenia gravis.
Bruce BB; Kupersmith MJ
J Neuroophthalmol; 2012 Sep; 32(3):212-5. PubMed ID: 22549563
[TBL] [Abstract][Full Text] [Related]
25. Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis.
Hu Y; Wang J; Rao J; Xu X; Cheng Y; Yan L; Wu Y; Wu N; Wu X
Int Immunopharmacol; 2020 Mar; 80():106130. PubMed ID: 31978800
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis.
Huang X; Qiu L; Lu Y; Chen J; Yang W; Ou C; Ran H; Liu W
Acta Neurol Belg; 2023 Feb; 123(1):153-160. PubMed ID: 34410678
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
Chirapapaisan N; Tanormrod S; Chuenkongkaew W
Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
[TBL] [Abstract][Full Text] [Related]
28. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Gratton SM; Herro AM; Feuer WJ; Lam BL
J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis.
Rao J; Li S; Wang X; Cheng Q; Ji Y; Fu W; Huang H; Shi L; Wu X
Front Med (Lausanne); 2022; 9():851808. PubMed ID: 35755064
[TBL] [Abstract][Full Text] [Related]
30. Single-fiber Electromyography in the Extensor Digitorum Communis for the Predictive Prognosis of Ocular Myasthenia Gravis: A Retrospective Study of 102 Cases.
Guan YZ; Cui LY; Liu MS; Niu JW
Chin Med J (Engl); 2015 Oct; 128(20):2783-6. PubMed ID: 26481746
[TBL] [Abstract][Full Text] [Related]
31. Pediatric Ocular Myasthenia Gravis.
Fisher K; Shah V
Curr Treat Options Neurol; 2019 Sep; 21(10):46. PubMed ID: 31559492
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
Benatar M; Mcdermott MP; Sanders DB; Wolfe GI; Barohn RJ; Nowak RJ; Hehir M; Juel V; Katzberg H; Tawil R;
Muscle Nerve; 2016 Mar; 53(3):363-9. PubMed ID: 26179124
[TBL] [Abstract][Full Text] [Related]
33. Diplopia in a patient presenting with "blurred vision": a case report.
Harrison A; Mudhar O; Yoo J; Rampal M
J Med Case Rep; 2023 Sep; 17(1):402. PubMed ID: 37679826
[TBL] [Abstract][Full Text] [Related]
34. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
Deng Y; Zhang X
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
[TBL] [Abstract][Full Text] [Related]
36. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Mullaney P; Vajsar J; Smith R; Buncic JR
Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.
Aguirre F; Villa AM
Eur Neurol; 2018; 79(3-4):113-117. PubMed ID: 29428956
[TBL] [Abstract][Full Text] [Related]
38. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.
Li M; Ge F; Guo R; Ruan Z; Gao Y; Niu C; Lin H; Zhao Z; Zhou Y; Li Z; Chang T
Ther Adv Neurol Disord; 2019; 12():1756286419876521. PubMed ID: 35173803
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
40. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
